読み込み中
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
前日終値
$1.89
+$0.08 · +4.42%
日中の時刻はETです。市場データは遅延する場合があります。
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
日中レンジ
現在 $1.89
52週レンジ
現在 $1.89
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
26
割高
センチメント
41
まちまち
リスク
76
高リスク
モメンタム
19
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
日中レンジ
現在 $1.89
52週レンジ
現在 $1.89
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | — | 2831.2万 USD |
| 売上原価 | 112.8万 USD | 117.8万 USD | 117万 USD | 105.7万 USD | 123.4万 USD |
| 粗利益 | −112.8万 USD | −117.8万 USD | −117万 USD | −105.7万 USD | 2707.8万 USD |
| 研究開発 | 2490.3万 USD | 3365.6万 USD | 2267.9万 USD | 1704.6万 USD | 4860.7万 USD |
| 販売・一般管理 | 1281.1万 USD | 1133万 USD | 1189.6万 USD | 563万 USD | 1777.8万 USD |
| 営業費用 | 3658.6万 USD | 4380.8万 USD | 3457.5万 USD | 2267.6万 USD | 6638.5万 USD |
| 受取利息 | 77.6万 USD | 77.7万 USD | 37.3万 USD | 6.48万 USD | 3392 USD |
| 支払利息 | 113.3万 USD | 45.5万 USD | 105.9万 USD | 359.58万 USD | 87.64万 USD |
| 減価償却費と償却費 | 112.8万 USD | 117.8万 USD | 117万 USD | 105.7万 USD | 25.15万 USD |
| 営業利益 | −3771.4万 USD | −4498.6万 USD | −3574.5万 USD | −2373.3万 USD | −3930.7万 USD |
| 純利益 | −3957.1万 USD | −5189.8万 USD | −3519.5万 USD | −2820.8万 USD | −2640.07万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは4件と限定的です
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2023年6月2日 | 1:10 | — | — |
発効済み 2023年6月2日
1:10
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI112.16万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM58.96万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF38.77万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO21.94万0.00%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO20.43万0.00%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC9.07万0.01%13.17億 USD0.60%$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG3.8万0.00%17億 USD0.06%$260.49+0.91%
iShares Russell 2500 ETFSMMD1.24万0.00%40.62億 USD0.23%$86.29+0.38%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
